Kristof Chwalisz
TAP Pharmaceutical Products Inc.
Lake Forest
Illinois 60045
USA
Name/email consistency: high
- A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Chwalisz, K., Larsen, L., Mattia-Goldberg, C., Edmonds, A., Elger, W., Winkel, C.A. Fertil. Steril. (2007)
- Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs). Chwalisz, K., Garg, R., Brenner, R., Slayden, O., Winkel, C., Elger, W. Reprod. Biol. Endocrinol. (2006)
- The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Chwalisz, K., Elger, W., Stickler, T., Mattia-Goldberg, C., Larsen, L. Hum. Reprod. (2005)
- Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Chwalisz, K., Perez, M.C., Demanno, D., Winkel, C., Schubert, G., Elger, W. Endocr. Rev. (2005)
- Selective progesterone receptor modulators (SPRMs): a novel therapeutic concept in endometriosis. Chwalisz, K., Garg, R., Brenner, R.M., Schubert, G., Elger, W. Ann. N. Y. Acad. Sci. (2002)
